Gur Roshwalb
Directeur/Membre du Conseil chez MiNA Therapeutics Ltd.
Profil
Gur A.
Roshwalb is currently a Director at KAHR Medical Ltd., Biosplice Therapeutics, Inc., and aMoon Ventures Y Sh Ltd.
He is also a Non-Executive Director at MiNA Therapeutics Ltd., and a Director at Viracta Subsidiary, Inc. and Altrubio, Inc. In the past, he served as the Chief Executive Officer at Celsus Therapeutics Plc and Akari Therapeutics Plc, and as President & Chief Executive Officer at Zywie LLC.
He was also a Director at Sunesis Pharmaceuticals, Inc. and a Vice President at Venrock Associates.
Additionally, he worked as a Senior Research Analyst at Piper Sandler & Co. (Broker) and as the Chief Resident at The Mount Sinai Medical Center, Inc. Dr. Roshwalb received his undergraduate degree from The Trustees of Columbia University in The City of New York, his doctorate from Albert Einstein College of Medicine, Inc., and his MBA from The Leonard N Stern School of Business.
Postes actifs de Gur Roshwalb
| Sociétés | Poste | Début |
|---|---|---|
MiNA Therapeutics Ltd.
 MiNA Therapeutics Ltd. BiotechnologyHealth Technology MiNA Therapeutics Ltd. develops RNA activation therapeutics. The firm's saRNA platform enables the development of new medicines that restore normal function to patients? cells. It applies technology and clinical know-how to transform the therapy landscape of cancer and other severe diseases. The company was founded by John J. Rossi, Nagy Habib and Pal Saetrom in 2008 and is headquartered in London, the United Kingdom. | Directeur/Membre du Conseil | 01/08/2020 |
Viracta Subsidiary, Inc.
 Viracta Subsidiary, Inc. BiotechnologyHealth Technology Viracta Subsidiary, Inc. engages in the development of proprietary viral gene activation therapy to address cancers associated with the Epstein-Barr virus. Its platform is designed as a targeted approach to treat a range of viral-associated cancers and other serious diseases. The company was founded by Ronald J. Berenson, Douglas V. Faller, George C. Hillman, Thalia Papayannopoulou, Susan P. Perrine, George Stamatoyannopoulos, and Robert Williams and is headquartered in Cardiff, CA. | Directeur/Membre du Conseil | 01/11/2020 |
aMoon Ventures Y Sh Ltd.
 aMoon Ventures Y Sh Ltd. Investment ManagersFinance aMoon Ventures Y Sh Ltd (aMoon Ventures) is an venture capital firm founded in 2016 by Marius Nacht and Dr. Yair Schindel. The firm is headquartered in Israel. | Private Equity Investor | 01/01/2019 |
Altrubio, Inc.
 Altrubio, Inc. Internet RetailRetail Trade Altrubio, Inc. is a clinical-stage biotechnology company based in Redwood City, CA. The company specializes in developing novel therapies leveraging immune checkpoint agonism to enhance the function of natural pathways to downregulate an overactivated immune system. Altrubio's pipeline includes two clinical stage product candidates: neihulizumab, an immune checkpoint agonist antibody targeting PSGl-1/CD162 that depletes unwanted activated T cells with proof of mechanism in four autoimmune and inflammatory diseases, and ABGN-107, an antibody-drug conjugate employing a unique enzyme cleavable hydrophilic self-immolative linker and targeting a gastrointestinal tumor antigen. The company was founded in 2000, and the CEO is Judy Chou. | Directeur/Membre du Conseil | 01/12/2020 |
KAHR Medical Ltd.
 KAHR Medical Ltd. Pharmaceuticals: MajorHealth Technology KAHR Medical Ltd. develops novel fusion protein pharmaceuticals for the treatment of cancer and autoimmune diseases. Its drug pipeline is built around the signal converter proteins a unique class of multi-functional therapeutic agents that convert signals sent from one cell to another. The firm?s therapeutic proteins integrate two functional units, enabling each one to elicit multiple cooperative functional endpoints. The company was founded by Mark L. Tykocinski in 2005 and is headquartered in Jerusalem, Israel. | Directeur/Membre du Conseil | 01/01/2021 |
Biosplice Therapeutics, Inc.
 Biosplice Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Biosplice Therapeutics, Inc. provides medical research and development for tissue-level regeneration. It develops therapeutics to address a range of degenerative diseases, regenerative medicine and oncology. The company was founded by Osman Kibar and John Hood in 2008 and is headquartered in San Diego, CA. | Directeur/Membre du Conseil | 01/04/2021 |
Anciens postes connus de Gur Roshwalb
| Sociétés | Poste | Fin |
|---|---|---|
| VIRACTA THERAPEUTICS, INC. | Directeur/Membre du Conseil | 08/06/2022 |
| AKARI THERAPEUTICS, PLC | Directeur Général | 29/05/2017 |
Piper Sandler & Co. (Broker)
 Piper Sandler & Co. (Broker) Investment Banks/BrokersFinance Piper Sandler & Co. (Broker) (PSC-Broker) is the full-service brokerage division of Piper Sandler & Co., a financial service firm headquartered in Minneapolis, Minnesota. They are a subsidiary of Piper Sandler Companies (NYSE: PIPR). The firm was founded in 1969 and previously known as Piper Jaffray & Co. They became Piper Sandler & Co. when Piper Jaffray Companies and Sandler O’Neill & Partners, L.P. merged to become Piper Sandler Companies in 2020. PSC-Broker provides brokerage and investment banking services to financial institutions, corporations and other financial investors. Their core focus sectors are Agriculture, renewables & cannabis, Business services, Chemicals & Materials, Consumer, Diversified industrials & services, Energy, Financial services, financial sponsors, Healthcare, and Technology. | Analyst-Equity | 30/11/2007 |
| ░░░ ░░░░░ ░░░░░ ░░░░░░░ ░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | - |
Formation de Gur Roshwalb
| The Trustees of Columbia University in The City of New York | Undergraduate Degree |
| Albert Einstein College of Medicine, Inc. | Doctorate Degree |
| The Leonard N Stern School of Business | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| AKARI THERAPEUTICS, PLC | Health Technology |
| VIRACTA THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 12 |
|---|---|
Venrock Associates
 Venrock Associates Investment ManagersFinance Venrock Associates is an Independent Venture Capital firm founded in 1969. The firm is headquartered in Palo Alto. | Finance |
Piper Sandler & Co. (Broker)
Piper Sandler & Co. (Broker) Investment Banks/BrokersFinance Piper Sandler & Co. (Broker) (PSC-Broker) is the full-service brokerage division of Piper Sandler & Co., a financial service firm headquartered in Minneapolis, Minnesota. They are a subsidiary of Piper Sandler Companies (NYSE: PIPR). The firm was founded in 1969 and previously known as Piper Jaffray & Co. They became Piper Sandler & Co. when Piper Jaffray Companies and Sandler O’Neill & Partners, L.P. merged to become Piper Sandler Companies in 2020. PSC-Broker provides brokerage and investment banking services to financial institutions, corporations and other financial investors. Their core focus sectors are Agriculture, renewables & cannabis, Business services, Chemicals & Materials, Consumer, Diversified industrials & services, Energy, Financial services, financial sponsors, Healthcare, and Technology. | Finance |
Sunesis Pharmaceuticals, Inc.
 Sunesis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sunesis Pharmaceuticals, Inc. engages in the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. The firm's activities include conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting clinical trials and raising capital. The company was founded on February 10, 1998 and is headquartered in South San Francisco, CA. | Health Technology |
Celsus Therapeutics Plc
 Celsus Therapeutics Plc Pharmaceuticals: MajorHealth Technology Celsus Therapeutics Plc is a drug development company, which focuses on developing novel, first-in-class, non-steroidal, synthetic anti-inflammatory drugs and multi-functional anti-inflammatory drugs. The company main clinical candidates are MRX-5, MRX-6, MRX-4, CFX-1 and OPX-1. Celsus Therapeutics was founded on October 7, 2004 and is headquartered in London, the United Kingdom. | Health Technology |
KAHR Medical Ltd.
KAHR Medical Ltd. Pharmaceuticals: MajorHealth Technology KAHR Medical Ltd. develops novel fusion protein pharmaceuticals for the treatment of cancer and autoimmune diseases. Its drug pipeline is built around the signal converter proteins a unique class of multi-functional therapeutic agents that convert signals sent from one cell to another. The firm?s therapeutic proteins integrate two functional units, enabling each one to elicit multiple cooperative functional endpoints. The company was founded by Mark L. Tykocinski in 2005 and is headquartered in Jerusalem, Israel. | Health Technology |
Biosplice Therapeutics, Inc.
Biosplice Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Biosplice Therapeutics, Inc. provides medical research and development for tissue-level regeneration. It develops therapeutics to address a range of degenerative diseases, regenerative medicine and oncology. The company was founded by Osman Kibar and John Hood in 2008 and is headquartered in San Diego, CA. | Commercial Services |
Zywie LLC
 Zywie LLC Pharmaceuticals: MajorHealth Technology Zywie LLC operates as a therapeutics company that focuses on the treatment of metabolic and neurodegenerative disorders. It engages in clinical development strategy and protein folding diseases. The company is headquartered in Princeton, NJ. | Health Technology |
The Mount Sinai Medical Center, Inc.
 The Mount Sinai Medical Center, Inc. Hospital/Nursing ManagementHealth Services The Mount Sinai Medical Center, Inc. operates charitable teaching hospitals. The non-profit company is based in New York, NY. The CEO of the company is Gino Santorio. | Health Services |
aMoon Ventures Y Sh Ltd.
aMoon Ventures Y Sh Ltd. Investment ManagersFinance aMoon Ventures Y Sh Ltd (aMoon Ventures) is an venture capital firm founded in 2016 by Marius Nacht and Dr. Yair Schindel. The firm is headquartered in Israel. | Finance |
Viracta Subsidiary, Inc.
Viracta Subsidiary, Inc. BiotechnologyHealth Technology Viracta Subsidiary, Inc. engages in the development of proprietary viral gene activation therapy to address cancers associated with the Epstein-Barr virus. Its platform is designed as a targeted approach to treat a range of viral-associated cancers and other serious diseases. The company was founded by Ronald J. Berenson, Douglas V. Faller, George C. Hillman, Thalia Papayannopoulou, Susan P. Perrine, George Stamatoyannopoulos, and Robert Williams and is headquartered in Cardiff, CA. | Health Technology |
Altrubio, Inc.
Altrubio, Inc. Internet RetailRetail Trade Altrubio, Inc. is a clinical-stage biotechnology company based in Redwood City, CA. The company specializes in developing novel therapies leveraging immune checkpoint agonism to enhance the function of natural pathways to downregulate an overactivated immune system. Altrubio's pipeline includes two clinical stage product candidates: neihulizumab, an immune checkpoint agonist antibody targeting PSGl-1/CD162 that depletes unwanted activated T cells with proof of mechanism in four autoimmune and inflammatory diseases, and ABGN-107, an antibody-drug conjugate employing a unique enzyme cleavable hydrophilic self-immolative linker and targeting a gastrointestinal tumor antigen. The company was founded in 2000, and the CEO is Judy Chou. | Retail Trade |
MiNA Therapeutics Ltd.
MiNA Therapeutics Ltd. BiotechnologyHealth Technology MiNA Therapeutics Ltd. develops RNA activation therapeutics. The firm's saRNA platform enables the development of new medicines that restore normal function to patients? cells. It applies technology and clinical know-how to transform the therapy landscape of cancer and other severe diseases. The company was founded by John J. Rossi, Nagy Habib and Pal Saetrom in 2008 and is headquartered in London, the United Kingdom. | Health Technology |
